![](https://www.canaan.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBcFlDIiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--c8f1d5d49a7b998901115b92b38c0fb60f2793d6/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9VWTI5dFltbHVaVjl2Y0hScGIyNXpld2M2QzNKbGMybDZaVWtpQ1RVeE1sNEdPZ1pGVkRvSmRISnBiVlE9IiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--227fdc48d0cc0381319025b1f375233c6a320fb3/envisia.png)
Envisia
Envisia develops long acting ophthalmologic drugs, bringing a revolutionary approach to advancing glaucoma and other pharmacotherapies.
Website
www.envisiatherapeutics.comPartner
Stephen BlochInvestment
Series A
Envisia develops long acting ophthalmologic drugs, bringing a revolutionary approach to advancing glaucoma and other pharmacotherapies.
Series A